Analysis of U.S. Patent 6,015,819: Scope, Claims, and Landscape
U.S. Patent 6,015,819, titled "Formulations comprising active compounds and one or more cyclodextrins," was granted to Pfizer, Inc. on January 18, 2000. This patent claims specific pharmaceutical formulations of sertraline hydrochloride complexed with cyclodextrins. The primary innovation lies in improved solubility and bioavailability of sertraline.
What is the core invention claimed in U.S. Patent 6,015,819?
The patent claims pharmaceutical compositions that include sertraline hydrochloride and one or more cyclodextrins. These cyclodextrins form inclusion complexes with sertraline hydrochloride, enhancing its solubility and dissolution rate compared to the free drug.
What are the key components of the claimed formulations?
The claimed formulations consist of:
- Active Compound: Sertraline hydrochloride.
- Complexing Agent: One or more cyclodextrins.
- Optional Excipients: Pharmaceutically acceptable carriers, diluents, binders, disintegrants, lubricants, and flavoring agents.
What specific cyclodextrins are encompassed by the patent claims?
The patent explicitly mentions several types of cyclodextrins, including:
- Alpha-cyclodextrin
- Beta-cyclodextrin
- Gamma-cyclodextrin
- Derivatives of these cyclodextrins, such as hydroxypropyl beta-cyclodextrin.
The claims broadly cover any cyclodextrin capable of forming an inclusion complex with sertraline hydrochloride.
What are the asserted benefits of these cyclodextrin complexes?
The primary benefits disclosed in the patent are:
- Increased Solubility: The formation of inclusion complexes significantly enhances the aqueous solubility of sertraline hydrochloride.
- Improved Dissolution Rate: This increased solubility leads to a faster rate at which the drug dissolves in biological fluids.
- Enhanced Bioavailability: Improved dissolution and solubility are expected to translate into higher and more consistent absorption of the drug in the body.
- Reduced Side Effects: By improving dissolution, lower doses might be achievable, potentially reducing gastrointestinal side effects associated with orally administered sertraline.
What is the scope of the patent's claims?
U.S. Patent 6,015,819 has 18 claims. These claims cover both the method of preparing the complex and the final pharmaceutical composition.
What does Claim 1 broadly claim?
Claim 1 is a composition claim and states: "A pharmaceutical composition comprising sertraline hydrochloride and one or more cyclodextrins, wherein the sertraline hydrochloride and the one or more cyclodextrins are co-precipitated from an aqueous solvent to form an inclusion complex." This claim establishes the core inventive concept of forming the complex through a specific co-precipitation method.
How do subsequent claims narrow or expand upon Claim 1?
Subsequent claims provide further specificity and variations:
- Claim 2: Specifies that the cyclodextrin is a beta-cyclodextrin.
- Claim 3: Specifies that the cyclodextrin is hydroxypropyl beta-cyclodextrin.
- Claim 4: Claims a composition wherein the molar ratio of sertraline hydrochloride to cyclodextrin is from 1:0.1 to 1:5.
- Claim 5: Claims a composition wherein the molar ratio is from 1:0.5 to 1:2.
- Claim 6: Claims a composition wherein the molar ratio is from 1:1 to 1:1.5.
- Claim 7: Claims a solid dosage form of the composition.
- Claim 8: Claims a tablet formulation.
- Claim 9: Claims a capsule formulation.
- Claim 10: Claims a method for preparing a pharmaceutical composition, comprising the steps of dissolving sertraline hydrochloride and one or more cyclodextrins in an aqueous solvent and co-precipitating the sertraline hydrochloride and cyclodextrins to form an inclusion complex.
- Claim 11: Claims the method of Claim 10, wherein the cyclodextrin is a beta-cyclodextrin.
- Claim 12: Claims the method of Claim 10, wherein the cyclodextrin is hydroxypropyl beta-cyclodextrin.
- Claim 13: Claims the method of Claim 10, wherein the molar ratio of sertraline hydrochloride to cyclodextrin is from 1:0.1 to 1:5.
- Claim 14: Claims the method of Claim 10, wherein the molar ratio is from 1:0.5 to 1:2.
- Claim 15: Claims the method of Claim 10, wherein the molar ratio is from 1:1 to 1:1.5.
- Claim 16: Claims the method of Claim 10, further comprising the step of formulating the inclusion complex into a solid dosage form.
- Claim 17: Claims the method of Claim 16, wherein the solid dosage form is a tablet.
- Claim 18: Claims the method of Claim 16, wherein the solid dosage form is a capsule.
The claims provide a tiered approach, starting with a broad composition and method and then detailing specific cyclodextrins, molar ratios, and dosage forms.
What is the patent landscape surrounding U.S. Patent 6,015,819?
The patent landscape for drug formulations is complex, involving numerous patents covering active pharmaceutical ingredients (APIs), formulations, manufacturing processes, and methods of use.
What is the relationship between U.S. Patent 6,015,819 and the active ingredient sertraline hydrochloride?
Sertraline hydrochloride is the active pharmaceutical ingredient. Patents covering the API itself, such as the original composition of matter patents for sertraline (e.g., U.S. Patent 4,536,518, also owned by Pfizer), typically expire earlier than formulation patents. U.S. Patent 6,015,819 is a formulation patent specifically designed to extend market exclusivity by covering novel ways to deliver sertraline.
What are other known patents related to sertraline formulations?
Numerous patents exist for sertraline, including:
- U.S. Patent 4,536,518: Covers the composition of matter for sertraline. This patent expired, opening the door for generic sertraline hydrochloride products.
- U.S. Patent 5,476,958: Claims specific crystalline forms (polymorphs) of sertraline hydrochloride. Polymorph patents can also significantly impact the generic market by preventing the use of specific, advantageous crystalline forms.
- U.S. Patent 6,008,229: This patent, also held by Pfizer, covers "Antidepressant-Cyclodextrin Complexes" and lists sertraline as one of the active compounds. It claims inclusion complexes of antidepressants with cyclodextrins and a process for their preparation. This patent is closely related to 6,015,819, potentially covering a broader class of antidepressants or slightly different complexation methods.
- Other formulation patents: Various companies have filed patents related to modified-release formulations, taste-masking technologies, and combinations with other active ingredients for sertraline.
How does the patent landscape affect generic competition for sertraline?
The patent landscape creates barriers to generic entry. While the primary API patent (4,536,518) has long expired, secondary patents like U.S. Patent 6,015,819, polymorph patents (e.g., 5,476,958), and patents on specific formulations can prevent generic manufacturers from launching their products or force them to develop non-infringing formulations. Generic companies must carefully navigate these patents, often challenging their validity or designing around them. The presence of multiple, overlapping patents requires thorough freedom-to-operate (FTO) analysis.
What is the current status and likely impact of U.S. Patent 6,015,819?
As of its grant date in 2000, U.S. Patent 6,015,819 would have had a term of 20 years from its filing date. The filing date for this patent was November 25, 1997. Therefore, its statutory term would have expired around November 25, 2017. Patent term extensions (PTE) under the Hatch-Waxman Act can extend patent life to compensate for regulatory review delays. However, without specific information on whether a PTE was granted for this patent, its effective market exclusivity period concluded in 2017 or later if extended.
The primary impact of this patent was to provide extended market exclusivity for a particular formulation of sertraline hydrochloride, likely contributing to the sustained market presence of Pfizer's branded Zoloft. For generic manufacturers, understanding the claims of this patent was crucial for developing and launching their own versions of sertraline, ensuring they did not infringe upon the patented cyclodextrin formulation.
Key Takeaways
- U.S. Patent 6,015,819 claims novel pharmaceutical compositions of sertraline hydrochloride complexed with cyclodextrins.
- The core innovation is enhanced solubility and dissolution rate of sertraline hydrochloride through cyclodextrin inclusion complexation, achieved via co-precipitation.
- The patent covers specific cyclodextrins (e.g., beta-cyclodextrin, hydroxypropyl beta-cyclodextrin), molar ratios, and dosage forms (tablets, capsules).
- This formulation patent served to extend market exclusivity for sertraline beyond the expiry of the active ingredient composition of matter patent.
- The patent's statutory term has expired, but any Patent Term Extensions (PTE) would have determined its precise end date for market exclusivity.
- The patent landscape for sertraline is complex, with multiple patents covering API, polymorphs, and various formulations, requiring careful freedom-to-operate analysis for generic entrants.
Frequently Asked Questions
Has U.S. Patent 6,015,819 expired?
The statutory term for U.S. Patent 6,015,819 would have expired approximately 20 years from its filing date of November 25, 1997, which is around November 25, 2017. However, if a Patent Term Extension (PTE) was granted by the USPTO to compensate for regulatory review delays, its effective period of exclusivity would be extended accordingly.
What specific therapeutic areas are addressed by sertraline?
Sertraline hydrochloride is primarily prescribed for the treatment of major depressive disorder, obsessive-compulsive disorder, panic disorder, social anxiety disorder, and post-traumatic stress disorder.
Can a generic manufacturer produce sertraline hydrochloride if U.S. Patent 6,015,819 was still active?
A generic manufacturer could only produce sertraline hydrochloride if they did not infringe any active patents. If U.S. Patent 6,015,819 was active and covered their intended formulation, they would need to either: (1) wait for the patent to expire, (2) obtain a license from the patent holder, (3) successfully challenge the patent's validity, or (4) develop a non-infringing formulation.
What is the significance of "co-precipitation" in the patent claims?
The co-precipitation method described in the patent is presented as a specific process for forming the inclusion complex. This method detail can be crucial for patentability, as it differentiates the claimed invention from other potential methods of complex formation.
How do cyclodextrin inclusion complexes improve drug delivery?
Cyclodextrins are cyclic oligosaccharides with a hydrophobic interior and a hydrophilic exterior. They can encapsulate lipophilic drug molecules within their cavity, forming an inclusion complex. This encapsulation increases the drug's apparent solubility in aqueous environments and can protect it from degradation, leading to improved absorption and bioavailability.
What is a "freedom-to-operate" analysis in the context of this patent?
A freedom-to-operate (FTO) analysis is a comprehensive review of existing patents to determine if a proposed product or process infringes any valid and enforceable intellectual property rights. For a generic drug manufacturer, an FTO analysis for sertraline would examine patents like U.S. Patent 6,015,819 to ensure their generic product does not violate any patent claims.
Citations
[1] Pfizer, Inc. (2000). U.S. Patent 6,015,819: Formulations comprising active compounds and one or more cyclodextrins. United States Patent and Trademark Office.
[2] Pfizer, Inc. (1985). U.S. Patent 4,536,518: 1-Aryl-4-arylaminotetralins. United States Patent and Trademark Office.
[3] Pfizer, Inc. (1995). U.S. Patent 5,476,958: Crystalline salts of 1-(4-chlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthylamine. United States Patent and Trademark Office.
[4] Pfizer, Inc. (1999). U.S. Patent 6,008,229: Antidepressant-Cyclodextrin Complexes. United States Patent and Trademark Office.
